1927nm 非剥脱点阵激光治疗眼周和口周皱纹的有效性与安全性研究

注册号:

Registration number:

ChiCTR2600126354 

最近更新日期:

Date of Last Refreshed on:

2026-06-08 11:44:49 

注册时间:

Date of Registration:

2026-06-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

1927nm 非剥脱点阵激光治疗眼周和口周皱纹的有效性与安全性研究

Public title:

Study on Efficacy and Safety of 1927 nm Non-Ablative Fractional Laser in the Treatment of Periorbital and Perioral Wrinkles

注册题目简写:

English Acronym:

研究课题的正式科学名称:

1927nm 非剥脱点阵激光治疗眼周和口周皱纹的有效性与安全性研究

Scientific title:

Study on Efficacy and Safety of 1927 nm Non-Ablative Fractional Laser in the Treatment of Periorbital and Perioral Wrinkles

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

谢丽 

研究负责人:

文翔 

Applicant:

Li Xie 

Study leader:

Xiang Wen 

申请注册联系人电话:

Applicant telephone:

+86 177 8861 8201

研究负责人电话:

Study leader's
telephone:

+86 189 8060 6449

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2497136131@qq.com

研究负责人电子邮件:

Study leader's E-mail:

xiangwen_wcums@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市武侯区国学巷37号

研究负责人通讯地址:

四川省成都市武侯区国学巷37号

Applicant address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

Study leader's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西医院皮肤性病科

Applicant's institution:

Department of Dermatology, West China Hospital, Sichuan University.

研究负责人所在单位:

四川大学华西医院皮肤性病科

Affiliation of the Leader:

Department of Dermatology, West China Hospital, Sichuan University.

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2026年审(966)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理审查委员会

Name of the ethic committee:

Biomedical Ethics Review Committee, West China Hospital, Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-05-26 00:00:00

伦理委员会联系人:

邓绍林

Contact Name of the ethic committee:

Deng Shaolin

伦理委员会联系地址:

四川省成都市武侯区国学巷37号

Contact Address of the ethic committee:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 8542 2654

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital, Sichuan University

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxue lane, Wuhou District, Chengdu, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

具体地址:

四川省成都市武侯区国学巷37号

Institution
hospital:

West China Hospital, Sichuan University

Address:

37 Guoxue lane, Wuhou District, Chengdu, Sichuan

经费或物资来源:

横向课题

Source(s) of funding:

Horizontal research project

研究疾病:

眼周及口周皱纹  

Target disease:

Periorbital and Perioral Wrinkles

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

评估1927nm非剥脱点阵激光治疗眼周和口周皱纹的有效性与安全性。  

Objectives of Study:

To evaluate the efficacy and safety of 1927 nm non-ablative fractional laser in the treatment of periorbital and perioral wrinkles.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 对近红外光敏感者; 2. 近期有暴晒史者或治疗后需要接触阳光者; 3. 入组前 1 年内进行过下眼睑手术者(包括眼袋手术、眼周提升术等); 4. 入组前 6 个月内眼周、口周接受过真皮内美塑(如透明质酸钠、胶原蛋白、自体脂肪)、肉毒素注射、埋线等治疗者; 5. 计划在研究期间进行面部医疗美容治疗者; 6. 治疗区域皮肤合并各种细菌、真菌、病毒等感染者; 7. 拟治疗区存在恶性肿瘤或不明性质的皮肤肿物; 8. 拟治疗区域存在开放性伤口; 9. 拟治疗区存在任何影响皱纹评判的合并疾病(黄褐斑、炎症后色素沉着、痤疮、口周皮炎、肉芽肿、湿疹、扁平疣、扁平苔藓等); 10. 凝血功能检查有异常或出凝血障碍病史或正在使用抗凝血剂; 11. 植入心脏起搏器、除颤器者; 12. 严重心、脑、肝、肾、肺、血液等系统性疾病者,自身免疫性疾病者、免疫缺陷者、全身性肌肉活动障碍者; 13. 有光敏性癫痫病史者; 14. 有鳞状细胞癌或黑色素瘤病史者; 15. 瘢痕体质者; 16. 正在接受化疗/放疗者; 17. 精神类疾病或情绪不稳定者; 18. 妊娠、哺乳期及备孕者; 19. 其他研究者判断不适宜纳入本研究的受试者。

Exclusion criteria:

1. Subjects with hypersensitivity to near-infrared light; 2. Subjects with recent excessive sun exposure or anticipated unavoidable sun exposure after treatment; 3. Subjects who have undergone lower eyelid surgery (including blepharoplasty, periorbital lifting, etc.) within 1 year prior to enrollment; 4. Subjects receiving intradermal mesotherapy (e.g., sodium hyaluronate, collagen, autologous fat), botulinum toxin injection, thread lifting or other relevant treatments on periorbital and perioral areas within 6 months prior to enrollment; 5. Subjects planning to receive any facial aesthetic procedures during the trial period; 6. Subjects with bacterial, fungal, viral or other cutaneous infections at target treatment sites; 7. Subjects with malignant tumors or undiagnosed cutaneous lesions in the intended treatment areas; 8. Subjects with open wounds within the intended treatment areas; 9. Subjects with concomitant skin disorders interfering with wrinkle assessment in target areas, including melasma, post-inflammatory hyperpigmentation, acne, perioral dermatitis, granuloma, eczema, verruca plana, lichen planus, etc.; 10. Subjects with abnormal coagulation tests, history of coagulation disorders, or ongoing anticoagulant medication; 11. Subjects implanted with cardiac pacemakers or defibrillators; 12. Subjects with severe systemic diseases involving heart, brain, liver, kidney, lung or hematological system, autoimmune diseases, immunodeficiency diseases, or systemic muscular movement disorders; 13. Subjects with a medical history of photosensitive epilepsy; 14. Subjects with past medical history of squamous cell carcinoma or melanoma; 15. Subjects with keloid diathesis/scar diathesis; 16. Subjects undergoing chemotherapy or radiotherapy; 17. Subjects with psychiatric disorders or unstable emotional status; 18. Pregnant, lactating women and females attempting conception; 19. Other subjects deemed inappropriate for study enrollment by investigators.

研究实施时间:

Study execute time:

From 2026-06-08 00:00:00 To 2027-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-08 00:00:00 To 2027-03-31 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

22

Group:

Intervention group

Sample size:

干预措施:

每例受试者的眼周及口周接受1927 nm非剥脱点阵激光(Lavieen,Wontech,韩国)治疗。每例受试者共治疗 3 次,每次间隔 1个月。

干预措施代码:

Intervention:

Each subject was treated with a 1927 nm non?ablative fractional laser (Lavieen, Wontech, South Korea) on the periorbital and perioral regions. All subjects received a total of three treatment sessions with a one?month interval between consecutive treatments.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

West China Hospital, Sichuan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

Fitzpatrick 皱纹分级

指标类型:

主要指标

Outcome:

Fitzpatrick wrinkle score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

GAIS 分级和全局美容效果反应率

指标类型:

次要指标

Outcome:

GAIS grading and global aesthetic effect response rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 35 years
最大 Max age 55 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据的采集与管理,均由研究者使用正版EXCEL软件完成。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The collection and management of data were all carried out by the researchers using the genuine EXCEL software.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-06-08 11:44:41